Halozyme Therapeutics, Inc. $HALO Shares Sold by Hodges Capital Management Inc.

Hodges Capital Management Inc. trimmed its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 21.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 120,206 shares of the biopharmaceutical company’s stock after selling 31,950 shares during the quarter. Hodges Capital Management Inc. owned about 0.10% of Halozyme Therapeutics worth $8,816,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in HALO. Campbell Newman Asset Management Inc. increased its position in Halozyme Therapeutics by 0.4% in the third quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company’s stock worth $2,705,000 after buying an additional 153 shares during the period. Alps Advisors Inc. grew its position in shares of Halozyme Therapeutics by 3.0% during the third quarter. Alps Advisors Inc. now owns 5,926 shares of the biopharmaceutical company’s stock worth $435,000 after acquiring an additional 170 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 174 shares during the period. Richardson Financial Services Inc. boosted its stake in Halozyme Therapeutics by 87.6% during the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 198 shares during the period. Finally, Brown Advisory Inc. boosted its stake in Halozyme Therapeutics by 0.6% during the 2nd quarter. Brown Advisory Inc. now owns 35,057 shares of the biopharmaceutical company’s stock valued at $1,824,000 after purchasing an additional 224 shares during the period. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $80.48 on Wednesday. The company has a 50-day moving average of $71.55 and a 200-day moving average of $70.25. The firm has a market cap of $9.46 billion, a price-to-earnings ratio of 16.94, a price-to-earnings-growth ratio of 0.33 and a beta of 0.97. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. Halozyme Therapeutics, Inc. has a twelve month low of $47.50 and a twelve month high of $82.22.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on HALO shares. The Goldman Sachs Group reaffirmed a “sell” rating and set a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Citizens Jmp increased their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research note on Tuesday, November 4th. JPMorgan Chase & Co. lifted their price objective on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research note on Monday, October 27th. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $77.44.

Insider Activity at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the sale, the director directly owned 40,123 shares of the company’s stock, valued at $2,818,640.75. This trade represents a 4.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total value of $1,522,400.00. Following the sale, the chief executive officer directly owned 708,719 shares in the company, valued at $53,947,690.28. This trade represents a 2.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 49,398 shares of company stock worth $3,650,592. 2.40% of the stock is currently owned by company insiders.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Reported record full‑year revenue ($1.397B) and raised visibility into 2026 — management reiterated guidance for materially higher 2026 revenue, sizable adjusted EBITDA and strong non‑GAAP EPS ranges, supporting forward growth expectations. HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE
• Positive Sentiment: Royalty momentum and inorganic tech adds — royalty revenue grew strongly (record $868M FY2025) and the company closed acquisitions of Hypercon technologies, which could expand product/enhancement mix and lift future royalty streams. HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE
• Positive Sentiment: Street sentiment remains constructive — broker consensus is skewed positive (moderate‑buy) with a median price target near current levels, giving upside support if guidance execution continues. HALO Receives Consensus Rating
• Neutral Sentiment: Top‑line beat but mixed quarter — Q4 revenue of ~$451.8M rose ~51.6% YoY and slightly topped estimates, showing continued ENHANZE/royalty strength even as profitability metrics were weak. Halozyme Surprises With Q4 CY2025 Sales
• Neutral Sentiment: Analyses are watching whether royalty momentum can sustain into 2026 — if royalties and new tech contributions track to guidance, upside is plausible; execution risk remains. Halozyme earnings in focus
• Negative Sentiment: Large EPS miss and reported Q4 loss — Halozyme reported EPS of ($0.24) versus street expectations materially higher (consensus ~+$1.9), producing investor concern about one‑time items, costs or non‑GAAP adjustments behind the gap. Halozyme Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Market reaction and deeper financial details — shares fell after the surprise loss; third‑party summaries show a sizable operating and net loss, rising liabilities and notable insider selling, all of which heighten near‑term risk sentiment. Halozyme Stock Falls on Q4 2025 Earnings

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.